Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.42 |
| ▸ | MAOB | P27338 | 9/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383375 | 0.88 | KMT2A (0.39) | MAOAMAOBKMT2ATP53HTR2C | |
| SCHEMBL1385607 | 0.83 | NPC1 (0.38) | TP53GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1383964 | 0.83 | NPC1 (0.38) | TP53GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1383468 | 0.83 | AR (0.41) | KMT2AHTR2CKMO | |
| SCHEMBL1386631 | 0.83 | AR (0.41) | KMT2AHTR2CKMO | |
| SCHEMBL1383974 | 0.80 | TRPA1 (0.38) | KMT2AHTR2CKMO | |
| SCHEMBL1386887 | 0.80 | TRPA1 (0.38) | KMT2AHTR2CKMO | |
| SCHEMBL1358821 | 0.75 | KMO (0.43) | MAOAMAOBKMOGABRG2GABRB3 | |
| SCHEMBL1386062 | 0.75 | HDAC1 (0.36) | TP53KMOGABRG2GABRB3GABRA5 | |
| SCHEMBL2321767 | 0.73 | TRPA1 (0.39) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4787321-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | claimed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | claimed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | claimed |
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | MAOA 1351/4885MAOB 495/4885KMT2A 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.